Tuberculosis: An Old Killer Proving Difficult To Best
Executive Summary
With the announcement that tuberculosis surpassed HIV/AIDS in attributable deaths from infectious diseases worldwide, there has been a renewed interest in the development of new treatments and regimens for dealing with what is now the world’s number one infectious disease killer.
You may also be interested in...
New GHIT Funding Supports Novel Malaria, TB Treatments, Diagnostics
Japan's GHIT Fund has made substantial new allocations for malaria and tuberculosis diagnosis and treatment that include extensive pharma industry participation in collaborative research projects.
Delamanid Access Widened But TB Groups Want More
Otsuka has agreed a plan with the Global Drug Facility to improve the worldwide distribution of its novel TB drug delamanid, but several access groups are asking for additional action to combat the multidrug-resistant form of the disease.
NIH 'XDR-tuberculosis' case spotlights drug resistance threat
The National Institutes of Health (NIH) on 8 June disclosed that a woman with extensively drug-resistant tuberculosis (XDR-TB), which is particularly difficult to treat, was admitted three days earlier to the agency's Clinical Center, where she is being treated in an isolation room.